Literature DB >> 11891481

Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer.

Y-S Lee1, J M Jeong, Y J Kim, J W Chung, J H Park, Y-G Suh, D S Lee, J-K Chung, M C Lee.   

Abstract

Radioisotope-labelled lipiodol has been used in the therapy of liver cancer. Recently a lipiodol solution of 188Re-labelled diaminedithiol (DD) has been reported to show a high uptake in the liver cancer. We synthesized long-chain alkyl DD derivatives to improve their uptake and retention in tissue. As the length of the alkyl chain increased, tissue uptake and retention also increased due to hydrophobic interaction with lipiodol. Among the synthesized compounds, the lipiodol solution of 188Re-HDD, the DD derivative with the longest side chain (C16), is a promising agent for therapy of liver cancer.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11891481     DOI： 10.1097/00006231-200203000-00006

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


  10 in total

Review 1.  Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

2.  (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.

Authors:  Bieke Lambert; Klaus Bacher; Luc Defreyne; Hans Van Vlierberghe; Jae Min Jeong; Rong Fu Wang; Jan van Meerbeeck; Peter Smeets; Roberto Troisi; Hubert Thierens; Filip De Vos; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

Review 3.  Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Authors:  Bieke Lambert; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

Review 4.  Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.

Authors:  Aysheh Alrfooh; Aditi Patel; Sandeep Laroia
Journal:  Nucl Med Mol Imaging       Date:  2021-07-13

Review 5.  KSNM60: The History of Radiopharmaceutical Sciences in Korea.

Authors:  Ran Ji Yoo; Yun-Sang Lee; Kyo Chul Lee; Dong Wook Kim; Dong-Yeon Kim; Yearn Seong Choe; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2022-04-05

6.  Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.

Authors:  Felix Sundram; Tran Chi Minh Chau; Peljee Onkhuudai; Patricia Bernal; Ajit Kumar Padhy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

7.  Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs.

Authors:  E Garin; N Noiret; C Malbert; N Lepareur; A Roucoux; S Caulet-Maugendre; A Moisan; J Lecloirec; J Y Herry; P Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-23       Impact factor: 9.236

8.  Radionuclide therapy of hepatocellular carcinoma.

Authors:  Fx Sundram
Journal:  Biomed Imaging Interv J       Date:  2006-07-01

Review 9.  188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

Authors:  Alessandra Boschi; Petra Martini; Licia Uccelli
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-19

Review 10.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.